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Amiodarone. an andsrrh~:hmic drug approved for use in patients 
who surlier csrdiar arrest. has bea asocialed with infiltralion of 
or inflammalar~ changes in various tissues. To date thyroid 
dysfunction has ken Ihe “nly endocrine disBrba”ce noted. In a” 
initial group ol sewn zvniodaranetrealed men undergoing e~aIu- 
adnn for .sexual d~sfonclion, an elwalioo in serum gonadotropin 
canceotrafian ws d&&d. suws,ine feslicolar dysfondion. 
Because of Lhis finding, goyedal ~onolion was. prospoclively 
evaluated In 44 men ,I8 who had bwn treated with smiadarone 
for 1, year and 26 sorvivors of cardlac ems, who had been 
,res,ed wilb anliarrhythmic drugs orher lhan amicdaronr,. Ami- 
odarone.,ns,ed mm had higher Strom follicle-s,imu,a,ing hor- 
mone 141.8 * 22.8 IS, 14.4 + 10.4 mlU/ml, p < 0.001) nod 
bdeinizing hormone 134.8 * 26.4 vs. 10.1 z? 5.2 mIUlml, p < 
O.OO,l concentrations compared with conrrol subjecls. Allhaugh 
Ammdarone is a po,en, antiarrhythmic drug used in survi- 
vors of sudden cardiac arrest. It is a benzofuran derivative 
that selectively prolongs the duration of the cardiac action 
polential ,I 2). Multiple rcpor,s (3) have described infiltra- 
&c or inflammalory char&s in o varie,y of tissues including 
rkin. cornea. peripheral nerve, skelclal muscle. liver and 
lung. To date. thyroid dysfunction is the only endocrine 
abnormaltly ,hat has been observed in amiodarone-treated 
patica~. Thyroid changes are attributable bolh 10 ,he iodine 
content of rhc drug (75 mg iodine/ZOO mg tablet) 14) and IO ils 
direct elf%, on the peripheral me,abolism of thyroid- 
stimulating honone (5). 
With the cxceo,ion of these thvroid chances. ma, side 
eRec,s of amioda~one are a,trib&ble 10 ils pharmacokine,- 
its. I, ih highly lipophilic and nearly camplelely metabolized 
(6,. Because ofrhese propenies. s,esdy slate concentlittions 
in ,hc plasma are achwed slowly and lhe drug’s accumulc 
lion within organs prolonga its elimination by severill months 
serum tata, nod free fesloslerooe ,eveIs were ramparable belveen 
Ihe ,wo patient groups, lhese levels were invelrely rowelad lr = 
-0.53. p < 0.05; r = -0.62, p < 0.01, rerpecdvely) with 
comula,ivr rmdodarooe dose. 
Hyprresponsivewss to (be admlnlstrntion of gonPdc4ropin. 
r&eslng hormone ws noted in Ihe IO amic&rooe~trea,ed men 
esaloaled by ibis dingoath ,a,. Sexur, dyslundion was common 
in bolh groups (70% ofcontrol rohjetts and 82% of smiodsrwr- 
lresled subjecel, allhoogh a,rophir ,&,a were more commonly 
obwwd in amicdamne~,rea,ed men lp < 0.1). 
Beraw of ,be elewded worn gonadotropin level, it L, eon. 
eluded lha, teslieulsr dysfunction may read, from pmlooged 
amiodamne treatnrent. 
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(71. Amiodamne concentrations have been found 10 be 50 
times higher in ,he lipid-laden testes than in the plasma (8). 
Several cases of epididymifis attributed 10 amiodarone use 
have been reponed (9.10). 
An inilial group of amiodarone-treated men referred ,o 
the Johns Hopkins Endocrine Clinic for sexual dysfunction 
were found 10 have depressed serom ,es,os,erooe and elewed 
follicle-stimularing hormone and luleinizing hormone levels. 
Serum tofal ,es,os,erone concen,ra,ions include both free tes- 
tos,erone and ,eslOs,erone bound to sex hormone-binding 
globulin. Sewn !u,einizing hormone and follicle-stimulating 
hormone are goonadofropins sweled in the anterior pituitary 
gland tha, sfimulale lestosterone synthesis in Ihe Leydig cell 
and spermatogenesis in the seminiferous tubules of the ,es,es. 
respectively. A hormonal pattern of a low serum ,es,os,emne 
and elevated follicle-stimulating hormone and luleinhing hor- 
mone levels sugge ,s tha, teslicolar dysfunction has occurred 
and ,har serum gosdotropins are being secreted in response. 
Because of lhese lindiw in amiodxone~,rea,ed men. we 
undemmk a prospective &xs.sec,ional study of consecutive 
men seen a, an arrhythmia clinic co ies, Ihe hypolhesis the, 
amiodamne use is associated wi,h ,es,iculu dysfunction indr- 
pendenl of sexual iunclion. 
Methods 
Study pnlienu. Men aged 121 years were recruiled from 
patients seen cowxutively a, The lohns Hopkins Cardinc 
Arrhythmia Clinic All p;menls had been reruscnaled aRsr 
an episode of out&hospilal cardiac arre\l and 4 wcrc 
receiving long-wrm anliarrhylhmic therapy for cuntr~l uf 
venlricular tachycardia. Men who had never l&en am<>)- 
darone were claaxified ar conlrol wbjec[>. All dmiodarone 
userr had been wealed with this drug for E I year. SubJecr* 
were excluded from the study ifthcy had il hwvy ofmumpi 
orchitis. had been expored co alkylacmp agwtc or raduwn 
therapy or had previously taken sex hormoner Eighlcr‘n 
men underwent a testicular examimuion b! one observer 
(A.S.D.) who did not know the lreatment x!aiu of foul 
(22%) of the patients. The wdy was approved by the Join1 
Committee on Clinical Isve~~~pat~on of The John, Hopkim 
Medical Inslituriona. Informed written cunwnt ~4, attained 
from all subjecrs. 
Clinical characteristics. Two groups of men were wdied 
IniMly. seven selected men who were bemE rrwed alrh 
aniudarone were referred to the endocrine clinic for ev.du- 
Iion of decreancd libido and were found II> hove ,Ibno~m,d 
gonadal function (Table I). In a wand wdy. 44 men t IS 
amiodarone-treated subJec& and 16 .omr ~I \ubject,l panic- 
ipated in this crowcectionzal prqxrtive study of :onaJ.d 
function. The mean age of lhc ammdanme proup IX!\ corn- 
parable wilh lhal of the WIWDI gruup 16X : X \i\ 65 I X 
and euradlol Slimulatory wling of Ihe gonadal axis. per- 
formed m 14 men. mcluded folhcle-,rimulating hormone and 
lutemizmg hormone dctcrmmations 30. 60 and 90 min after 
the inllavcnou, bolua administration of 100 yg gonadotro- 
pin-releasing hormone (Factrel). a hyporhalamic-rclcasing 
hormone that atlmulaleb secretion of both sewm luteinizing 
hormone and follicle-stimulating hormone. This endocrine 
lest is commonly used lo evaluate pituitary function. 
Hormone assays. The concentmtinns of serum prolactin 
(Tandem-RPrL. Hybritechl. follicle-stlmalating hormone 
and lulcinizing hormone (Amerlex. Pmerr’lam). testoster- 
one (ICN Biomedical Diagnostic DivisionI. free lertoclerone 
and e,tradiol (Free T and Ewadiol Coal-A-Count. Diagnos- 
tic ProJuclsl were measured by standard radioimmunoarray 
technique,. 
Data analysis. Data are expressed as mean vrducs * SD. 
The Swdcnt’a r test for unpaired data was used to compare 
mean valueb of the two palient groups. Panial correlation 
coefficients (X,1 were determined 10 evaluaw the ra.(ionb 
among vanables. The null hypothesis for the differences 
between lhe IWO paiienl groups was rejected when a p value 
4 0.05 ~a( obtained. St&&al analysis was performed with 
use of SAS @AS lnslitutes. Inc.) and CLlNFO (Bolt. 
Baranek and Newman. Inc.) software programs. The lotal 
lifetime amiodarone dose was calculated by multiplying the 
dally dose by lhe duratinn of drug use. 
RWlltS 
Basal endocrine tin&n (Table 2). Serum folliclc-slim- 
ulating hormone concentration lcvcls ‘were significantly ele- 
vdled to a mean value of41.8 r 22.8 mlU/ml in Ihe amiodamne 
groupcompared wth 14.4 + 10.4 mlUiml in the control group 
(p < O.OOI). Similarly, the mean serum level of lutemizing 
hormone in the amiodarone group was 34.8 t 26.4 compared 
with IO.1 t 5.2 mlU/ml in the conlrol group (p < O.Wl). 
Basal worn total testosterone, free lestoscerone. prolaclin 
and eslradiol levels were not significandy different in the 
amiodarone-treated patients compared with patients in the 
coolrol group (Table 21. Although the level of xrum thyrox- 
ine was slightly hxher in the amiadarone than in the conlrol 
group CY.5-? 5.3 vi. 1.4 + I .? pddl, respectively. p < 0.05; 
normal range 5.5 LO 11.5). the serum thyroid-stimulating 
hormone cancentralion was actually lowei (4.7 + 2.1 vs. 
3.6 ? 3.6 pg/dl in the amiodarone versus control group. 
p < 0.05; normal range 0.05 lo 5). 
Torol lifehtw omiudmmr dust (dose x years of frcat- 
mentl, adjusting for age. wac inversely correlated with free 
Lrilosterone (I = -0.53. p < 0.05) and Lotal testosterone (r = 
-0.62, p = 0.01) and (with borderhnc SLalisticaI significance) 
directly correlated to serum follicle-slimulaling hormone 
concefilration levels V = 0.46, p = 0.07). No relntion was 
noled beween loLaI amiodaronc dose and serum luleinizing 
hormone levels (r = U.34, p = NSI. Although age adjusted 
for Ihe cumulalive amiodarone dose of the amiodarone- 
trcaled men was inversely correlated with serum total les. 
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Figure 1. Serum follicle-stimulating hormone (FSH) (lap) and 
lutemizing hormone 0.H) (bMmml levels 30, M)and 90 min afier Lhe 
intravenous administradon ofgonadotropin-rrlearing hormone in 10 
amiadarone-frcaled (opon circb) and 4 control fclowd ~IrnTle~) sub- 
jects (mean ? SD). *p < 0.05 amiodarone-treated versus conlrol 
wbjeets, The ShsdPd arear indicate the normal range of values. 
tosterone (r = -0.57. p c 0.05) and follicle-stimulating 
hormone level (r = 0.40, p = 0.12). it was independent of 
serum free testos~rone and luteinizing hormone levels. 
When both groups were analyzed together, age was corre- 
lated with serum follicle-stimulating hormone levels (r = 
0.32, p < 0.05). 
limulated endocrine bnctian. A gonadotropin-releasing 
hormone (Fig. II stimulation lest was performed in 14 
padents 110 amiodarone-lreated and 4 control patients). 
There were no stafislical differences noted belween groups 
in the area-under-the-response curve or in the maximal 
percent change from baseline YBIUCS. The serum follicle- 
stimulating hormone response was significantly elevated in 
Ihe amiodamne versus the control groups al 30 (p < 0.005). 
60 (p < O.WSl and Yo (p < 0.05) min. 
Sexual function. The frequency of reported sexual dys- 
funclion was similar m the amiodarone-treated and control 
palients. In :he amiodarose-treated group 9 (82%) of I I men 
reponed sexual dysfunction. Of these oiae, six had de- 
creased libido and erectile ability, two had diminished libido 
only, and one had impotence only. In the control group. 14 
(70%) of 20reporIed some ~crual dyrfuncdon. Oftbcsr. six 
(40%) had a decrease in libido and erectde function. seven 
(53%) had decreased lihidoonlv and one (7% had impotence 
OIIIY. 
Physical examination. A testicviar examinauon per- 
formed by one obserw (A.S.D.1 detected bdateral soft 
testes in / (9%) of tt control subjects ad m 4 (58%) of 7 
amiodarone-treated men (p < 0.05 comparing the two 
groups). The serum follicle-stimulating hormone concentra- 
[ions in this subset of patients were 35.6 2 17.0 and 37.5 2 
17.0 mlU:ml in the control and the amiodarone group. 
respectively. Serum testosterone levels did not correlate 
well with results of the examination. The warn testosterone 
concentralion was 277 ddl in the corm\ paticnts and 744 + 
176 rcgidl in the amiodarone-treated men. No other signs of 
decreased virilization were noted on physical eranunation. 
Discussion 
We describe an initial group of men Ireled with amio- 
damne who reported sexual dysfunction and were found to 
have testicular dysfunction. In a pmspective study of men 
recruited consecutively without regard to sexual function. 
amiodamne use was associated with elevated serum gonad- 
otrooin levels. Althouah the mean free testosterone concen- 
tratibn was maintainedin the group as a whole. the elevated 
serum follicle-stimulating hormone and luteinizing hotmone 
levels suggest testicular dysiunct+ 
Role of age. The hormonal chwges observed in these 
amiodarone-treated men were adjusted for differences m 
we. However, age had so independent effect on ioollicle- 
stimulating hormone concentration levels in both groups of 
men. Gonadal hormone levels have been “otrd 10 chase 
gradually in men aged >70 years iI 1.12). Clearly. obtaining 
serum hormone levels in these men at a younger age or 
before amiodarone treatment would have been helpful. Con. 
centrations of sex hormone-binding globulin have been ob- 
served to increase with increasing age. thus falsely elevatmg 
serum testosterone levels. We attempted to control for thiq 
effect by determining serum free testosterone levels. Sexual 
function in aging men is extremely variable and has been 
related to sexualitv at vouwer aces (131. In this sludv we 
attempted to qualiiy &pea; of ~enual iuncuon by asking 
patients about changer in activity rather than about level of 
activity. 
Role of chronic illness. Chronic illness is unlikely to 
account for elevations in serum gonadotropm levels. Studies 
in postmenopausal women in intensive care units suggest 
that a decline in serum follicle-stimulating hormone and 
luteinizing horwooe coocemraillmos consistent with a sick 
gonadotroph (14) Similarly. low output cardiac failure has 
been associated with low serum iolbcle-stimulating horroone 
levels (IS). This elfect is similar to the depresred gonadal 
axisobsewed in patients wth Starvation or anorexia nervosa 
1161. 
Hole of the hypothalamus or pituitary. It is unbkely that 
nmiodarune GIE centrally al the level ofthe hypothalamus or 
pituitary. Adura et al. t 171 found that growth and develop- 
mcnt in chddren treawd with amiodarone cerc normal and 
predommandy dependent on thyroid slatus although Ihey 
did not measure serum growth hormone levels. However. it 
IS intriauiw that amiodarone has been found to directlr 
stimulate thyro!d-stimulating hormone at the genomic level 
in the rat pnultary 118). Although this effect is probably 
unique ro the Thyroid axis. a direct etTecct of amiodarone on 
the gonadotroph cannot be excluded. 
Medicatmnr all&t sexual iunclion. but digoxin has been 
disproved as a cause of gonadal impairment in healthy men 
119) and onlv one amiodarone-treated man was takme a 
beta-adrenrr& blocking agent. 
Role of thyreid dysfunction. Because ammdorone may 
alter concentrations of sex-hormone-binding globulin 0d) 
and thur confound serum total ~cstosterone levels, serum 
free te,tostsrone concentrations were determined. Primary 
hypothyroidism has been associated with hvperconadotmoic 
hy&gonadnm. tu+ular awophy and drcre~~ed fen&y 
Cl). In lkis tudy. the amiadarooe-treated men had sbghtly 
higher serum rhyroxw and lower thyroid-srimulating hor- 
mone levelx (although both were ulell wthin ,he noren, 
rangee) compared wtth levels in control men. Because serum 
free trilodothyronine levels were not measured. some pa- 
ttents may have undetected euthyroid-sick syndrome (221. 
However. because all patients were ambulatory and not 
hospaahzed. lhn diagnoxc “ouiu oc UII,~~IIIIIUI,. :,L;ss: 
ingly. clcvattd gonadotropin and serum testosterone con- 
centrations were reported by Wonsman et al. (231 in three 
men taking amiodarone. In thex patients. correction of 
thyroid status djd not decrease gonadal serum levels. No 
connection with the effects of amiodarone was made m that 
ApOti. 
Mshanism of amiodarone eiiect. The mechanism by 
which amiodarone affects testicular function is no1 clear. 
Amiodarone appears 10 accwmdate in the gonad m Ihe same 
roamer as in other organs. as summrted by a previous report 
that amiodarone I& in test& barenchyma were 50 times 
higher than plasma levels I71 and that desethylamiodarone. a 
mctabulile of the drug, has been measured in semen 124). 
Simdarly. sterile epididymitis has been observed in b II 1%) 
oi 56 mw treated with smiodarone (9.10). A photomicro- 
graph ui the epididvmis showed focal fibrosis and lympho- 
cytic infiltratIon (9). which may be similar IO the interstitial 
and alveolar fibrosis and inflammation noted on Lund bioosv 
125.26). On eleclron micmscopy, multilamcllated $soso&l 
inclusions have been observed in conjunction with wide- 
spread ohoapholipidosis 07,281. In light of the elevated 
worn follicle-stimulating hormone levels and atrophic tes- 
ter. WC predict that a similar mechanism m the testes causes 
impaired spermatogenesis. Ii this theory is true. it is crucial 
to monitor these levels in younger men because of their 
sAects on fertility. Uniortunatcly, we were unable to obtain 
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